Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older (Reprinted from MMWR, vol 61, pg 394-395, 2012)

被引：0
|
作者：
不详
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 308卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：663 / 664
页数：2
相关论文
共 50 条
  • [41] Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50Years and Older presenting with community-acquired pneumonia in Israel
    Regev-Yochay, Gili
    Chowers, Michal
    Chazan, Bibiana
    Gonzalez, Elisa
    Gray, Sharon
    Zhang, Zhou
    Pride, Michael
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (10) : 2527 - 2532
  • [42] Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
    Solanki, Bhagirath B.
    Juergens, Christine
    Chopada, Manojkumar B.
    Supe, Pravin
    Sundaraiyer, Vani
    Le Dren-Narayanin, Natacha
    Cutler, Mark W.
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) : 2065 - 2071
  • [43] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
    Bryant, K. A.
    Frenck, R.
    Gurtman, A.
    Rubino, J.
    Treanor, J.
    Thompson, A.
    Jones, T. R.
    Sundaraiyer, V.
    Baxter, L. M.
    Gruber, W. C.
    Emini, E. A.
    Scott, D. A.
    Schmoele-Thoma, B.
    VACCINE, 2015, 33 (43) : 5854 - 5860
  • [44] Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age
    Greenberg, Richard N.
    Gurtman, Alejandra
    Frenck, Robert W.
    Strout, Cynthia
    Jansen, Kathrin U.
    Trammel, James
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2014, 32 (20) : 2364 - 2374
  • [45] An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana
    Brenda Anna Kwambana-Adams
    Franklin Asiedu-Bekoe
    Badu Sarkodie
    Osei Kuffour Afreh
    George Khumalo Kuma
    Godfred Owusu-Okyere
    Ebenezer Foster-Nyarko
    Sally-Ann Ohene
    Charles Okot
    Archibald Kwame Worwui
    Catherine Okoi
    Madikay Senghore
    Jacob Kweku Otu
    Chinelo Ebruke
    Richard Bannerman
    Kwame Amponsa-Achiano
    David Opare
    Gemma Kay
    Timothy Letsa
    Owen Kaluwa
    Ebenezer Appiah-Denkyira
    Victor Bampoe
    Syed M. A. Zaman
    Mark J. Pallen
    Umberto D’Alessandro
    Jason M. Mwenda
    Martin Antonio
    BMC Infectious Diseases, 16
  • [46] Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥ 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012 December 31, 2015
    Haber, Penina
    Arana, Jorge
    Pilishvili, Tamara
    Lewis, Paige
    Moro, Pedro L.
    Cano, Maria
    VACCINE, 2016, 34 (50) : 6330 - 6334
  • [47] An outbreak of pneumococcal meningitis among older children (≥ 5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana
    Kwambana-Adams, Brenda Anna
    Asiedu-Bekoe, Franklin
    Sarkodie, Badu
    Afreh, Osei Kuffour
    Kuma, George Khumalo
    Owusu-Okyere, Godfred
    Foster-Nyarko, Ebenezer
    Ohene, Sally-Ann
    Okot, Charles
    Worwui, Archibald Kwame
    Okoi, Catherine
    Senghore, Madikay
    Otu, Jacob Kweku
    Ebruke, Chinelo
    Bannerman, Richard
    Amponsa-Achiano, Kwame
    Opare, David
    Kay, Gemma
    Letsa, Timothy
    Kaluwa, Owen
    Appiah-Denkyira, Ebenezer
    Bampoe, Victor
    Zaman, Syed M. A.
    Pallen, Mark J.
    D'Alessandro, Umberto
    Mwenda, Jason M.
    Antonio, Martin
    BMC INFECTIOUS DISEASES, 2016, 16
  • [48] PNEUMOCOCCAL VACCINATION WITH 13-VALENT POLYSACCHARIDE CONJUGATE VACCINE FOR OLDER ADULTS WITH CHRONIC CONDITIONS: BUDGET IMPACT ANALYSIS IN COLOMBIA
    LaRotta, J.
    Sanchez, Reyes J. M.
    Gamboa, Castano N.
    VALUE IN HEALTH, 2022, 25 (01) : S107 - S107
  • [49] Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ngamprasertchai, Thundon
    Ruenroengbun, Narisa
    Kajeekul, Rattagan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):
  • [50] An Open-label Trial to Assess the Safety of 13-Valent Pneumococcal Conjugate Vaccine in Older Adults, Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.
    Schwarz, T. F.
    Pauksens, K.
    Juergens, C.
    Jayawardene, D.
    Emini, E. A.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S30 - S30
12345